Health & bio

FDA Approves Langlara (Insulin Glargine-aldy) as Lantus Interchangeable Biosimilar

Sanofi's insulin glargine-aldy (Langlara) approved April 29 as interchangeable Lantus biosimilar. Expands insulin options and reduces patient burden.

Primary sources · 1
FDA
← View the full 2026-04-30 (Thursday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →